Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Makefield Therapeutics Licenses Patent Rights Covering Its Hybrid Nanoparticle Delivery Platform from Albert Einstein College of Medicine

Abstract:
Uses Include Topical Antimicrobial and Erectile Dysfunction Therapies

Makefield Therapeutics Licenses Patent Rights Covering Its Hybrid Nanoparticle Delivery Platform from Albert Einstein College of Medicine

Newtown, PA | Posted on December 21st, 2009

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform. Makefield Therapeutics is utilizing two different topical formulations of the nitric oxide (NO)-containing nanoparticles in its therapeutic development programs: an antimicrobial for the treatment of drug resistant skin and soft tissue infections; and a topical treatment for Erectile Dysfunction (ED) in men unresponsive or dissatisfied with currently available oral drug treatments.

"Nitric oxide, Science Magazine's 1992 ‘Molecule of the Year,' has been the focus of immense medical and scientific exploration," said Robert Towarnicki, president and chief executive officer of Makefield Therapeutics "Until now, however, the difficulty of conveniently and effectively delivering the gas to targeted tissues has limited the therapeutic application of nitric oxide. The inventors at Einstein, led by Joel Friedman, MD, PhD, have developed a novel method for storing and delivering nitric oxide in a therapeutically relevant manner, through the use of biodegradable nanoparticles constructed of ‘Generally Recognized as Safe' (GRAS) components. We are very pleased to gain access to this promising drug delivery platform, for which the inventors have already published proof-of-concept in several very high value applications."

Mr. Towarnicki noted that multiple, published peer-reviewed articles have demonstrated in animal models the therapeutic potential of the nitric oxide-containing nanoparticles, both as a broad-spectrum antimicrobial and as a topical treatment for erectile dysfunction. Makefield Therapeutics plans to develop these two lead indications commercially and expand the uses of the technology to address other therapeutic applications where the Hybrid Nanoparticle™ technology platform can be enabling.

About the "Hybrid Nanoparticles™ Technology Platform

Hybrid Nanoparticles™ have for the first time enabled the practical delivery of therapeutic amounts of nitric oxide gas (NO) in a local, controlled, and sustained manner. The platform is also capable of delivering peptides, nucleic acids and traditional small molecule pharmaceuticals, both as single therapeutic entities and in combination treatments as well.

Multiple routes of administration including transdermal/topical, oral, intravenous, intraperitoneal, and instillation are possible utilizing this technology. The delivery system is capable of providing for immediate, pulsatile and sustained controlled drug release both locally and systemically.

The delivery system is biodegradable and utilizes excipients that are Generally Recognized as Safe (GRAS), USP-NF listed or previously utilized in medical applications. All of the components of the drug delivery system are commercially available in pharmaceutical grade and the methods of preparation use well-known pharmaceutical unit operations that easily lend themselves to scale up and manufacture.

####

About Makefield Therapeutics
Makefield Therapeutics, Inc., founded in July 2009, is a privately held therapeutics company with two development programs addressing large market opportunities in anti-infectives and the treatment of erectile dysfunction. Both programs are based on an innovative nanoparticle drug delivery platform with the potential to generate a pipeline of additional novel therapeutics.

For more information, please click here

Contacts:
Robert J. Towarnicki
President and CEO

(215) 321-5713

For Media
Joan Kureczka
Kureczka/Martin Associates
(415) 821 2413

Copyright © Makefield Therapeutics

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

Products

Spectradyne Partners with Particle Technology Labs for Measurement Services December 6th, 2018

Mode-Changing MEMS Accelerometer from STMicroelectronics Combines High Measurement Resolution and Ultra-Low Power for Industrial Applications November 7th, 2018

Fat-Repellent Nanolayers Can Make Oven Cleaning Easier October 17th, 2018

Aculon, Inc. Enters into Strategic Partnership Agreement with Henkel Corporation to Supply Key Mobile Device Manufacturers with NanoProof® PCB Waterproof Technology October 17th, 2018

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

Patents/IP/Tech Transfer/Licensing

Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023

Study finds nanomedicine targeting lymph nodes key to triple negative breast cancer treatment: In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cance May 13th, 2022

Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021

Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project